CHO cell
/ Zhongyi Anke Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
June 05, 2023
An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults.
(PubMed, Emerg Microbes Infect)
- "Further assays of single point mutations showed that K444T, L452R, N460K, or F486V was key mutations to cause immune evasion. Together, these data suggest that SCOK-Omicron can be used as a booster vaccine candidate in adults receiving subunit protein or inactivated vaccine in response to the epidemic of COVID-19 Omicron subvariants, and the mutation K444T, L452R, N460K, or F486V needs to be considered in future vaccine design."
Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
September 20, 2022
A randomized, double-blind, placebo-controlled phase 1 and phase 2 clinical trial to evaluate efficacy and safety of a SARS-CoV-2 vaccine SCoK in adults.
(PubMed, Clin Transl Med)
- "Additionally, the incidence of adverse reactions decreased significantly in phase 2 clinical trial. The vaccine SCoK was well tolerated and immunogenic."
Clinical • Journal • P1 data • P1 data • P2 data • P2 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
March 31, 2022
Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)
(clinicaltrials.gov)
- P1 | N=216 | Recruiting | Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Trial completion date: Jan 2022 ➔ Jul 2022
Trial completion date • Infectious Disease • Novel Coronavirus Disease
March 31, 2022
Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)
(clinicaltrials.gov)
- P2 | N=480 | Recruiting | Sponsor: Jiangsu Province Centers for Disease Control and Prevention | Trial primary completion date: Jul 2021 ➔ Jul 2022
Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
May 25, 2021
Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)
(clinicaltrials.gov)
- P1; N=216; Recruiting; Sponsor: Jiangsu Province Centers for Disease Control and Prevention; Trial primary completion date: Apr 2021 ➔ Dec 2021
Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
March 24, 2021
Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells)
(clinicaltrials.gov)
- P2; N=480; Recruiting; Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease
January 08, 2021
Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell)
(clinicaltrials.gov)
- P1; N=216; Recruiting; Sponsor: Jiangsu Province Centers for Disease Control and Prevention; Trial primary completion date: Dec 2020 ➔ Apr 2021
Clinical • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease
November 19, 2020
Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (CHO Cell)
(clinicaltrials.gov)
- P1; N=216; Recruiting; Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
1 to 8
Of
8
Go to page
1